Article
Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis - 1 Jan 2000
Hooimeijer Louise H, Stein-Wit Marjet A, Voskuilen Marja Aj, Lukens Michaël V, Meijer Karina, Mäkelburg Anja Bu, Tamminga Rienk Yj
Abstract excerpt
In 2018, Refacto AFR, a B-domain-deleted third-generation FVIII concentrate, became our preferential product. After the introduction, the development of inhibitors was prospectively monitored; retrospectively, we sought for risk factors in the patients who developed a de-novo inhibitor. Over a period of 15 months, 4/19 adult patients with non-severe haemophilia who were treated on demand for surgery, developed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.